|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.17 USD | +0.18% |
|
-5.62% | +7.62% |
| 03-03 | Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| 02-26 | Neurogene announces FDA breakthrough therapy designation for NGN-401 gene therapy for Rett syndrome | RE |
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NEUROGENE INC. | Other Biotechnology & Medical Research | +0.18% | -5.62% | +7.62% | +28.30% | - | 343M |  |  | |
- Stock Market
- Equities
- NGNE Stock
- Charts Neurogene Inc.
- Relative Strength Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition